New insights into the pathogenesis and treatment of anthrax toxin-induced shock

Bibliography

• HOLTY JE, BRAVATA DM, LIU H et al.: Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann. Intern. Med. (2006) 144:270-280.
   PubMed Web of Science ®Google Scholar
• JERNIGAN JA, STEPHENS DS, ASHFORD DA: Bioterrorrissm-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. (2001) 7:933-944.
   PubMed Web of Science ®Google Scholar
• SHERER K, LI Y, CUI X, EICHACKER PQ: Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy. Am. J. Respir. Crit. Care Med. (2007) 175:211-221.
   PubMed Web of Science ®Google Scholar
• LEPPLA SH: Anthrax toxin. In: Bacterial Proteins. Aktories K, Just I (Eds), New York, NY: Springer (2000):445-472.
   Google Scholar
• COLLIER RJ, YOUNG JA: Anthrax toxin. Ann. Rev. Cell Dev. Biol. (2003) 19:45-70.
   PubMed Web of Science ®Google Scholar
• XU L, FRUCHT DM: Bacillus anthracis: a multi-faceted role for anthrax lethal toxin in thwarting host immune defenses. Int. J. Biochem. Cell Biol. (2007) 39:20-24.
   PubMed Web of Science ®Google Scholar
• RAINEY GJA, YOUNG JAT: Antitoxins: novel strategies to target agents of bioterrorism. Nat. Rev. Microbiol. (2004) 2:721-726.
   PubMed Web of Science ®Google Scholar
• PETOSA C, COLLIER RJ, KLIMPEL KR et al.: Crystal structure of the anthrax toxin protective antigen. Nature (1997) 385:833-838.
   PubMed Web of Science ®Google Scholar
• BRADLEY KA, MOGRIDGE J, MOUREZ M et al.: Identification ofthe cellular receptor for anthrax toxin. Nature (2001) 414:225-229.
   PubMed Web of Science ®Google Scholar
• SCOBIE HM, RAINEY GJ, BRADLEY KA, YOUNG JA: Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl. Acad. Sci. USA (2003) 100:5170-5174.
   PubMed Web of Science ®Google Scholar
• LACY DB, WIGELSWORTH DJ, SCOBIE HM et al.: Crystal structure of the von Willebrand factor A domain of human capillary morphogenesis protein 2: an anthrax toxin receptor. Proc. Natl. Acad. Sci. USA (2004) 101:6367-6372.
   PubMed Web of Science ®Google Scholar
• SCOBIE HM, WIGELSWORTH DJ, MARLETT JM et al.: Anthrax toxin receptor 2-dependent lethal toxin killing in vivo. PLoS Pathog. (2006) 2(10):e111.
   PubMed Web of Science ®Google Scholar
• GORDON VM, KLIMPEL KR, ARORA N et al.: Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect. Immun. (1995) 63:82-87.
   PubMed Web of Science ®Google Scholar
• ABRAMI L, LIU S, COSSON P et al.: Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J. Cell Biol. (2003) 160:321-328.
   PubMed Web of Science ®Google Scholar
• CHEKANOV AV, REMACLE AG, GOLUBKOV VS et al.: Both PA63 and PA83 are endocytosed within an anthrax protective antigen mixed heptamer: a putative mechanism to overcome a furin deficiency. Arch. Biochem. Biophys. (2006) 446:52-59.
   PubMed Web of Science ®Google Scholar
• MOGRIDGE J, CUNNINGHAM K, LACY DB et al.: The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. Proc. Natl. Acad. Sci. USA (2002) 99:7045-7048.
   PubMed Web of Science ®Google Scholar
• MOGRIDGE J, CUNNINGHAM K, COLLIER RJ: Stoichiometry of anthrax toxin complexes. Biochemistry (2002) 41:1079-1082.
   PubMed Web of Science ®Google Scholar
• WEI W, LU Q, CHAUDRY GJ et al.: The LDL receptor-related protein LRP6 mediates internalization and lethality of anthrax toxin. Cell (2006)124:1141-1154.
   PubMed Web of Science ®Google Scholar
• YOUNG JJ, BROMBERG-WHITE JL, ZYLSTRA C et al.: LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality from anthrax lethal toxin. PLoS Pathog. (2007) 3(3):e27.
   PubMed Web of Science ®Google Scholar
• RAINEY GJA, WIGELSWORTH DJ, RYAN PL, SCOBIE HM, COLLIER RJ, YOUNG JA: Receptor-specific requirements for anthrax toxin delivery into cells. Proc. Natl. Acad. Sci. USA (2005) 102:13278-13283.
   PubMed Web of Science ®Google Scholar
• PANNIFER AD, WONG TY, SCHWARZENBACHER R et al.: Crystal structure of the anthrax lethal factor. Nature (2001) 414:229-233.
   PubMed Web of Science ®Google Scholar
• DUESBERY NS, WEBB CP, LEPPLA SH et al.: Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science (1998) 280:734-737.
   PubMed Web of Science ®Google Scholar
• SMITH H, KEPPIE J, STANLEY JL: The chemical basis of the virulence of Bacillus anthracis. V. The specific toxin produced by B. Anthracis in vivo. Br. J. Exp. Pathol. (1955) 36:460-472.
   PubMed Web of Science ®Google Scholar
• STANLEY JL, SMITH H: Purification of Factor I and recognition of a third factor of the anthrax toxin. J. Gen. Microbiol. (1961) 26:49-63.
   PubMedGoogle Scholar
• ECKERT NJ, BONVENTRE PF: In vivo effects of B. anthracis culture filtrates. J. Infect. Dis. (1963) 112:226-232.
   Web of Science ®Google Scholar
• BEALL FA, DALLDORF FG: The pathogenesis of the lethal effect of anthrax toxin in the rat. J. Infect. Dis. (1966) 116:377-389.
   PubMed Web of Science ®Google Scholar
• FISH DC, KLEIN F, LINCOLN RE et al.: Pathophysiological changes in the rat associated with anthrax toxin. J. Infect. Dis. (1968) 118:114-124.
   PubMed Web of Science ®Google Scholar
• VICK JA, LINCOLN RE, KLEIN F et al.: Neurological and physiological responses of the primate to anthrax toxin. J. Infect. Dis. (1968) 118(1):85-96.
   PubMed Web of Science ®Google Scholar
• CUI X, MOAYERI M, LI Y et al.: Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2004) 286:R699-R709.
   PubMed Web of Science ®Google Scholar
• CUI X, LI Y, MOAYERI M et al.: Late treatment with a protective antigen derived monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J. Infect. Dis. (2005) 191:422-434.
   PubMed Web of Science ®Google Scholar
• HANNA PC, ACOSTA D, COLLIER RJ: On the role of macrophages in anthrax. Proc. Natl. Acad. Sci. USA (1993) 90:10198-10201.
   PubMed Web of Science ®Google Scholar
• BALDARI CT, TONELLO F, PACCANI SR, MONTECUUCO C: Anthrax toxins: a paradigm of bacterial immune suppression. Trends Immunol. (2006) 27(9):434-440.
   PubMed Web of Science ®Google Scholar
• PELLIZZARI R, GUIDI-RONTANI C, VITALE G et al.: Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNγ-induced release of NO and TNF. FEBS Lett. (1999) 462:199-204.
   PubMed Web of Science ®Google Scholar
• ERWIN JL, DASILVA LM, BAVARI S et al.: Macrophage-derived cell lines do not express proinflammatory cytokines after exposure to Bacillus anthracis lethal toxin. Infect. Immun. (2001) 69:1175-1177.
   PubMed Web of Science ®Google Scholar
• DANG O, NAVARRO L, ANDERSON K, DAVID M: Cutting edge: anthrax lethal toxin inhibits activation of IFN-regulatory factor 3 by lipopolysaccharide. J. Immunol. (2004) 172:747-751.
   PubMed Web of Science ®Google Scholar
• FANG H, CORDOBA-RODRIGUEZ R, LANKFORD CSR, FRUCHT DM: Anthrax lethal toxin blocks MAPK kinase-dependent IL-2 production in CD4+ T cells. J. Immunol. (2005) 174:4966-4971.
   PubMed Web of Science ®Google Scholar
• AGRAWAL A, LINGAPPA J, LEPPLA SH et al.: Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature (2003) 424:329-334.
   PubMed Web of Science ®Google Scholar
• MOAYERI M, HAINES D, YOUNG HA, LEPPLA SH: Bacillus anthracis lethal toxin induces TNF-α-independent hypoxia-mediated toxicity in mice. J. Clin. Invest. (2003) 112:670-682.
   PubMed Web of Science ®Google Scholar
• CUI X, LI Y, LI X et al.: Sublethal doses of Bacillus anthracis lethal toxin inhibit inflammation with lipopolysaccharide and Escherichia coli challenge but have opposite effects on survival. J. Infect. Dis. (2006) 193(6):829-840.
   PubMed Web of Science ®Google Scholar
• KIRBY JE: Anthrax lethal toxin induces human endothelial cell apoptosis. Infect. Immun. (2004) 72:430-439.
   PubMed Web of Science ®Google Scholar
• WARFEL JM, STEELE AD, D’AGNILLO F: Anthrax lethal toxin induces endothelial barrier dysfunction. Am. J. Pathol. (2005) 166:1871-1881.
   PubMed Web of Science ®Google Scholar
• GOZES Y, MOAYERI M, WIGGINS JF, LEPPLA SH: Anthrax lethal toxin induces ketotifen-sensitive intradermal vascular leakage in certain inbred mice. Infect. Immun. (2006) 74:1266-1272.
   PubMed Web of Science ®Google Scholar
• CULLEY NC, PINSON DM, CHAKRABARTY A et al.: Pathological manifestations in mice exposed to anthrax lethal toxin. Infect. Immun. (2005) 73:7006-7010.
   PubMed Web of Science ®Google Scholar
• MOAYERI M, WEBSTER JI, WIGGINS JF et al.: Endocrine perturbation increases susceptibility to anthrax lethal toxin. Infect. Immun. (2005) 73:4238-4244.
   PubMed Web of Science ®Google Scholar
• BOYDEN ED, DIETRICH WF: Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat. Genet. (2006) 38:240-244.
   PubMed Web of Science ®Google Scholar
• POPOV SG, VILLASMIL R, BERNARDI J et al.: Lethal toxin of Bacillus anthracis causes apoptosis of macrophages. Biochem. Biophys. Res. Commun. (2002) 293:349-355.
   PubMed Web of Science ®Google Scholar
• PARK JM, GRETEN FR, LI Z, KARIN M: Macrophage apoptosis by anthrax lethal factor through p38 inhibition. Science (2002) 297:2048-2051.
   PubMed Web of Science ®Google Scholar
• WRIGHT GC, MANDELL GI: Anthrax toxin blocks priming of neutrophils by lipopolysaccharide and by muramyl dipeptide. J. Exp. Med. (1986) 164:1700-1709.
   PubMed Web of Science ®Google Scholar
• DURING RL, LI W, HAO B et al.: Anthrax lethal toxin paralyzes neutrophil actin-based motility. J. Infect. Dis. (2005) 192:837-845.
   PubMed Web of Science ®Google Scholar
• CRAWFORD MA, AYLOTT CV, BOURDEAU RW, BOKOCH GM: Bacillus anthracis toxins inhibit human neutrophil NADPH oxidase activity. J. Immunol. (2006) 176:7557-7565.
   PubMed Web of Science ®Google Scholar
• PACCANI SR, TONELLO F, GHITTONI R et al.: Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J. Exp. Med. (2005) 201:325-331.
   PubMed Web of Science ®Google Scholar
• COMER JE, CHOPRA AK, PETERSON JW, KONIG R: Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo. Infect. Immun. (2005) 73:8275-8281.
   PubMed Web of Science ®Google Scholar
• ROSSI PACCANI S, TONELLO F, PATRUSSI L et al.: Anthrax toxins inhibit immune cell chemotaxis by perturbing chemokine receptor signalling. Cell. Microbiol. (2006) Epub ahead of print.
   Google Scholar
• FANG H, XU L, CHEN TY et al.: Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production.J. Immunol. (2006) 176:6155-6161.
   PubMed Web of Science ®Google Scholar
• GUIDI-RONTANI C, WEBER-LEVY M, MOCK M, CABIAUX V: Translocation on B. anthracis lethal and oedema factors across endosome membranes. Cell Microbiol. (2000) 2:259-264.
   PubMed Web of Science ®Google Scholar
• NEUMEYER T, TONELLO F, DAL MOLIN F et al.: Anthrax edema factor, voltage-dependent binding to the protective antigen ion channel and comparison to LF binding. J. Biol. Chem. (2006) 281(43):32335-32343.
   PubMed Web of Science ®Google Scholar
• LACY DB, MOUREZ M, FOUASSIER A, COLLIERS RJ: Mapping the anthrax protective antigen binding site on the lethal and edema factors. J. Biol. Chem. (2002) 277:3006-3010.
   PubMed Web of Science ®Google Scholar
• LEPPLA SH: Anthrax toxin edema factor: A bacterial adenylate cyclase that increases cyclic AMP concentrations in eukaryotic cells. Proc. Natl. Acad. Sci. USA (1982) 79:3162-3166.
   PubMed Web of Science ®Google Scholar
• DAL MOLIN F, TONELLO F, LADANT D et al.: Cell entry and cAMP imaging of anthrax edema toxin. EMBO J. (2006) 25:5405-5413.
   PubMed Web of Science ®Google Scholar
• SHEN Y, ZHUKOVSKAYA NL, GUO Q et al.: Calcium-independant calmodulin binding and two-metal-ion catalytic mechanism of anthrax edema factor. EMBO J. (2005) 24:929-941.
   PubMed Web of Science ®Google Scholar
• AHUJA N, KUMAR P, BHATNAGAR R: The adenylate cyclase toxins. Crit. Rev. Microbiol.(2004) 30:187-196.
   PubMed Web of Science ®Google Scholar
• KUMAR P, AJUJA N, BHATNAGAR R: Anthrax edema toxin requires influx of calcium for inducing cyclic AMP toxicity in target cells. Infect. Immun. (2002) 70:4997-5007.
   Google Scholar
• MALDONADO-AROCHO FJ, FULCHER JA, BENHUR L, BRADLEY KA: Anthrax edema toxin induces anthrax toxin receptor expression in moncyte-derived cells. Mol. Microbiol. (2006) 61:324-337.
   PubMed Web of Science ®Google Scholar
• HAMBLETON P, CARMAN JA, MELLING J: Anthrax: the disease in relation to vaccines. Vaccine (1984) 2:125-132.
   PubMedGoogle Scholar
• FIROVED AM, MILLER GF, MOAYERI M et al.: Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am. J. Pathol. (2005) 167:1309-1320.
   PubMed Web of Science ®Google Scholar
• CUI X, LIY, LI X et al.: B. Anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model. J. Infect. Dis. (2007) 195:572-580.
   PubMed Web of Science ®Google Scholar
• MURRAY KJ: Cyclic AMP and mechanisms of vasodilation. Pharmacol. Ther. (1990) 47:329-345.
   PubMed Web of Science ®Google Scholar
• KATZ AM: Signal transduction: receptors, coupling proteins, and second messengers. In: Physiology of the Heart. Philadelphia: Lippincott, Williams and Wilkins (2001):255-286.
   Google Scholar
• TOURNIER J, QUESNEL-HELLMANN A, MATHIEU J et al.: Anthrax edema toxin cooperated with lethal toxin to impair cytokine secretion during infection of dendritic cells. J. Immunol. (2005) 174:4934-4941.
   PubMed Web of Science ®Google Scholar
• KRAKAUER T, LITTLE SF, STILES BG: Bacillus anthracis edema toxin inhibits Staphylococcus aures enterotoxin B effects in vitro: a potential protein therapeutic? Infect. Immun. (2005) 73:7069-7073.
   PubMed Web of Science ®Google Scholar
• HOOVER DL, FRIEDLANDER AM, ROGERS LC et al.: Anthrax edema toxin differentially regulates lipopolysaccharide-induced monocyte production of tumor necrosis factor alpha and interleukin-6 by increasing intracellular cyclic AMP. Infect. Immun. (1994) 62:4432-4439.
   PubMed Web of Science ®Google Scholar
• O’BRIEN J, FRIEDLANDER A, DREIER T et al.: Effects of anthrax toxin components on human neutrophils. Infect. Immun. (1985) 47:306-310.
   PubMed Web of Science ®Google Scholar
• TANAKA M, HASEGAWA T, OKAMOTO A et al.: Effect of antibiotics on Group A Streptococcus exoprotein production analyzed by two-dimensional gel electrophoresis. Antimicrob. Agents Chemother. (2005) 49:88-96.
   PubMed Web of Science ®Google Scholar
• BEEB E, ZHONG J, CLAGETT M et al.: Protection against inhalation anthrax-induced lethality by a human monoclonal antibody to protective antigen in rabbits and cynomologous monkeys [abstract B-33]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology (2003):47.
   Google Scholar
• LI Y, CUI X, HALEY M et al.: Fluids have opposing effects on survival comparing lipopolysaccharide (LPS) and Bacillus anthracis lethal toxin (LeTx) challenge in rats. Am. J. Resp. Crit. Care. Med. (2005) 2:A39.
   Google Scholar
• LI Y, CUI X, SU J et al.: Increases in blood pressure with norepinephrine improve survival with LPS but not lethal toxin challenge in rats. Am. J. Resp. Crit. Care Med. (2007) 4:A39.
   Google Scholar
• MOHAMED N, CLAGETT M, LI J et al.: A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect. Immun. (2005) 73:795-802.
   PubMed Web of Science ®Google Scholar
• PETERSON JW, COMER JE, NOFFSINGER DM et al.: Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect. Immun. (2006) 74:1016-1024.
   PubMed Web of Science ®Google Scholar
• SUBRAMANIAN GM, CRONIN PW, POLEY G et al.: A Phase I study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin. Infect. Dis. (2005) 41:12-20.
   PubMed Web of Science ®Google Scholar
• MAYNARD JA, MAASSEN CBM, LEPPLA SH et al.: Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. (2002) 20:597-601.
   PubMed Web of Science ®Google Scholar
• CHEN Z, MOAYERI M, ZHOU Y et al.: Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J. Infect. Dis. (2006) 193:625-633.
   PubMed Web of Science ®Google Scholar
• MABRY R, RANI M, GEIGER R et al.: Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an fc region. Infect. Immun. (2005) 73:8362-8368.
   PubMed Web of Science ®Google Scholar
• SAWADA-HIRAI R, JIANG I, WANG F et al.: Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J. Immune Based Ther. Vaccines (2004) 2:5.
   Google Scholar
• WILD MA, XIN H, MARUYAMA T et al.: Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat. Biotechnol. (2003) 21:1305-1306.
   PubMed Web of Science ®Google Scholar
• VITALE L, BLANSET D, LOWY I et al.: Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect. Immun. (2006) 74:5840-5847.
   PubMed Web of Science ®Google Scholar
• SINGH Y, KHANNA H, CHOPRA AP, MEHRA V: A dominant-negative mutant of Bacillus anthracis protective antigen inhibits anthrax toxin in vivo. J. Biol. Chem. (2001) 276:22090-22094.
   PubMed Web of Science ®Google Scholar
• SELLMAN BR, MOUREZ M, COLLIER RJ: Dominant–negative mutants of a toxin subunit: an approach to therapy of anthrax. Science (2001) 292:695-697.
   PubMed Web of Science ®Google Scholar
• KARGINOV VA, NESTOROVICH EM, YOHANNES A et al.: Search for cyclodextrin-based inhibitors of anthrax toxins: synthesis, structural features, and relative activities. Antimicrob. Agents Chemother. (2006) 50:3740-3753.
   PubMed Web of Science ®Google Scholar
• BACKER MV, PATEL V, JEHNING BT et al.: Inhibition of anthrax protective antigen outside and inside the cell. Antimicrob. Agents Chemother. (2007) 51:245-251.
   PubMed Web of Science ®Google Scholar
• SARAC MS, PEINADO JR, LEPPLA SH, LINDBERG I: Protection against anthrax toxemia by hexa-d-arginine in vitro and in vivo. Infect. Immun. (2004) 72:602-605.
   PubMed Web of Science ®Google Scholar
• JIAO GS, CREGAR L, WANG J et al.: Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine. Proc. Natl. Acad. Sci. USA (2006) 103:19707-19712.
   PubMed Web of Science ®Google Scholar
• MOAYERI M, WIGGINS JF, LINDMAN RE, LEPPLA SH: Cisplatin inhibition of anthrax lethal toxin. Antimicrob. Agents Chemother. (2006) 50:2658-2665.
   PubMed Web of Science ®Google Scholar
• ZHAO P, LIANG X, KALBFLEISCH J et al.: Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model. Hum. Antibodies (2003) 12:129-135.
   PubMedGoogle Scholar
• LIM N, KIM J, OH MS et al.: An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin. Infect. Immun. (2005) 73:6547-6551.
   PubMed Web of Science ®Google Scholar
• MIN D, TANG W, MRKSICH M: Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor. Nat. Biotechnol. (2004) 22:717-723.
   PubMed Web of Science ®Google Scholar
• PANCHAL RG, HERMONE AR, NGUYEN TL et al.: Identification of small molecule inhibitors of anthrax lethal factor. Nat. Struct. Mol. Biol. (2004) 11:67-72.
   PubMed Web of Science ®Google Scholar
• FORINO M, JOHNSON S,WONG TY et al.: Efficient synthetic inhibitors of anthrax lethal factor. Proc. Natl. Acad. Sci. USA (2005) 102:9499-9504.
   PubMed Web of Science ®Google Scholar
• DELLAICA I, DONA M, TONELLO F et al.: Potent inhibitors of anthrax lethal factor from green tea. EMBO Rep. (2004) 5:418-422.
   PubMed Web of Science ®Google Scholar
• MOUREZ M, KANE RS, MOGRIDGE J et al.: Designing a polyvalent inhibitor of anthrax toxin. Nat. Biotechnol. (2001) 19:958-961.
   PubMed Web of Science ®Google Scholar
• JOSHI A, SAARAPH A, POON V et al.: Synthesis of potent inhibitors of anthrax toxin based on poly-l-glutamic acid. Bioconjug. Chem. (2006) 17:1265-1269.
   PubMed Web of Science ®Google Scholar
• BASHA S, RAI P, POON V et al.: Polyvalent inhibitors of anthrax toxin that target host receptors. Proc. Natl. Acad. Sci. USA (2006) 103:13509-13513.
   PubMed Web of Science ®Google Scholar
• RAI P, PADALA C, POON V et al.: Statistical pattern matching facilitates the design of polyvalent inhibitors of anthrax and cholera toxins. Nat. Biotechnol. (2006) 24:582-586.
   PubMed Web of Science ®Google Scholar
• KUZMIC P, CREGAR L, MILLIS SZ, GOLDMAN M: Mixed-type noncompetitive inhibition of anthrax lethal factor protease by aminoglycosides. FEBS J. (2006) 273:3054-3062.
   PubMed Web of Science ®Google Scholar
• GOLDMAN ME, CREGAR L, NGUYEN D et al.: Cationic polyamines inhibit anthrax lethal factor protease. BMC Pharmacol. (2006) 6:8.
   PubMedGoogle Scholar
• JIAO GS, SIMO O, NAGATA M et al.: Selectively guanidinylated derivatives of neamine. Syntheses and inhibition of anthrax lethal factor protease. Bioorg. Med. Chem. Lett. (2006) 16(19):5183-5189.
   PubMed Web of Science ®Google Scholar
• MOAYERI M, WICKLIFFE KE, WIGGINS JF, LEPPLA SH: Oxidized ATP protection against anthrax lethal toxin. Infect. Immun. (2006) 74:3707-3714.
   PubMed Web of Science ®Google Scholar
• HIRSH MI, MANOV I, COHEN-KAPLAN V, IANCU TC: Ultrastructural features of lymphocyte suppression induced by anthrax lethal toxin and treated with chloroquine. Lab. Invest. (2006) Dec 18: Epub ahead of print.
   PubMedGoogle Scholar
• TONELLO F, SEVESO M, MARIN Oet al.: Screening inhibitors of anthrax lethal factor. Nature (2002) 418:386.
   PubMedGoogle Scholar
• TURK BE, WONG TY, SCHWARZENBACHER R et al.: The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat. Struct. Mol. Biol. (2004) 11:60-66.
   PubMed Web of Science ®Google Scholar
• SHEN Y, ZHUKOVSKAYA NL, ZIMMER MI et al.: Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc. Natl. Acad. Sci. USA (2004) 101:3242-3247.
   PubMed Web of Science ®Google Scholar
• SOELAIMAN S, WEI BQ, BERGSON P et al.: Structure-based inhibitor discovery against adenyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J. Biol. Chem. (2003) 278:25990-25997.
   PubMed Web of Science ®Google Scholar
• WALSH JL, PESIK N, QUINN CP et al.: A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor.CID (2007) 44:968-971.
   PubMed Web of Science ®Google Scholar